A nanoparticle-based vaccine candidate for H5N1 avian influenza achieved 100% protection in preclinical trials, offering hope ...

Lead researcher and CEO of POP Biotechnologies, Dr. Jonathan Lovell is based at the University at Buffalo. Dr. Lovell said ...

Search for other works by this author on: ...

A vaccine under development has demonstrated complete protection in mice against a deadly variant of the virus that causes bird flu. The work focuses on the H5N1 variant known as 2.3.4.4b, which has ...

China has made significant progress in vaccine development and immunization, marked by a growing portfolio of domestically ...

The company says its vaccine is on track for full approval, following delay. Novavax shares soared following the announcement ...

Proven effective for COVID-19, vaccine platform could be key in responding to evolving bird flu strains A developmental ...